Trial Details
RECRUITINGBasic Information
| Clinical ID | c510 |
|---|---|
| Identifier | NCT05702879 |
| Trial Title | Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Ozanimod|DRUG: TNF Inhibitor|DRUG: Steroids|DRUG: Vedolizumab|DRUG: Ustekinumab |
Participant Information
| Sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| City | Bern |
| Country/Region | Switzerland |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | OBSERVATIONAL |
|---|---|
| Phase | - |
Time Information
| Start Date | 2023-09-06 |
|---|---|
| Primary Completion Date | 2025-01-31 |
| Completion Date | 2025-01-31 |